|  Help  |  About  |  Contact Us

Publication : STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets.

First Author  Bader CS Year  2020
Journal  Sci Transl Med Volume  12
Issue  552 PubMed ID  32669421
Mgi Jnum  J:292361 Mgi Id  MGI:6448877
Doi  10.1126/scitranslmed.aay5006 Citation  Bader CS, et al. (2020) STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets. Sci Transl Med 12(552)
abstractText  The stimulator of interferon genes (STING) pathway has been proposed as a key regulator of gastrointestinal homeostasis and inflammatory responses. Although STING reportedly protects against gut barrier damage and graft-versus-host disease (GVHD) after major histocompatibility complex (MHC)-mismatched allogeneic hematopoietic stem cell transplantation (aHSCT), its effect in clinically relevant MHC-matched aHSCT is unknown. Studies here demonstrate that STING signaling in nonhematopoietic cells promoted MHC-matched aHSCT-induced GVHD and that STING agonists increased type I interferon and MHC I expression in nonhematopoietic mouse intestinal organoid cultures. Moreover, mice expressing a human STING allele containing three single-nucleotide polymorphisms associated with decreased STING activity also developed reduced MHC-matched GVHD, demonstrating STING's potential clinical importance. STING(-/-) recipients experienced reduced GVHD with transplant of purified donor CD8(+) T cells in both MHC-matched and MHC-mismatched models, reconciling the seemingly disparate results. Further examination revealed that STING deficiency reduced the activation of donor CD8(+) T cells early after transplant and promoted recipient MHC class II(+) antigen-presenting cell (APC) survival. Therefore, APC persistence in STING pathway absence may account for the increased GVHD mediated by CD4(+) T cells in completely mismatched recipients. In total, our findings have important implications for regulating clinical GVHD by targeting STING early after aHSCT and demonstrate that an innate immune pathway has opposing effects on the outcome of aHSCT, depending on the donor/recipient MHC disparity.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

17 Bio Entities

Trail: Publication

0 Expression